Morroniside in Ischemic Stroke: Preclinical Evidence and a Proposed Stage-Dependent Framework for Neurovascular Repair
International Journal of Molecular Sciences · 12.11.2026 · 27 (22) · 10155
DOI: 10.3390/ijms272210155 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.11.2026. Verfasst von Ling Zhu und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Science and Technology Commission.
Themen: Schlaganfall
Abstract (Originalsprache)
Ischemic stroke remains a leading cause of death and long-term disability. Although thrombolysis and mechanical thrombectomy have improved reperfusion, secondary neurovascular injury and incomplete tissue repair remain important challenges. Morroniside (MOR), an iridoid glycoside from Cornus officinalis, has shown neuroprotective and repair-associated effects in experimental stroke models. This narrative review synthesizes preclinical evidence from 11 eligible in vivo cerebral ischemia or post-stroke recovery studies identified through searches of PubMed, Web of Science, and Scopus. Reported findings associate MOR treatment with changes in neuroinflammation, pyroptosis, oxidative stress, apoptosis, blood–brain barrier (BBB) integrity, angiogenesis, and neural progenitor responses. On this basis, we propose a hypothesis-generating, stage-dependent framework that organizes injury-associated and repair-associated outcomes according to their reported post-ischemic timing. These outcomes may represent complementary aspects of MOR activity, but because the findings derive from separate experiments, they do not establish a validated temporal sequence or stage-specific treatment regimen. Inconsistent methodological reporting and unresolved questions about brain exposure, target engagement, treatment timing, and safety also limit translational interpretation. MOR therefore merits further investigation as a potential adjunct to reperfusion and rehabilitation, although its efficacy and therapeutic window require rigorous validation before clinical application.
Förderung
- Beijing Municipal Science and Technology Commission
Zitieren
APA
Zhu, L., Sun, F., Ma, Y., Li, D., Liu, T., Tian, X., Zheng, W., Zhu, Z., Wang, Y., & Wang, W. (2026). Morroniside in Ischemic Stroke: Preclinical Evidence and a Proposed Stage-Dependent Framework for Neurovascular Repair. International Journal of Molecular Sciences, 27(22), 10155. https://doi.org/10.3390/ijms272210155
Vancouver
Zhu L, Sun F, Ma Y, Li D, Liu T, Tian X, et al. Morroniside in Ischemic Stroke: Preclinical Evidence and a Proposed Stage-Dependent Framework for Neurovascular Repair. International Journal of Molecular Sciences. 2026;27(22):10155. doi:10.3390/ijms272210155
BibTeX
@article{Zhu2026,
author = {Zhu, Ling and Sun, Fangling and Ma, Yifu and Li, Dan and Liu, Tingting and Tian, Xin and Zheng, Wenrong and Zhu, Zixin and Wang, Yufeng and Wang, Wen},
title = {Morroniside in Ischemic Stroke: Preclinical Evidence and a Proposed Stage-Dependent Framework for Neurovascular Repair},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10155},
doi = {10.3390/ijms272210155}
}
EUVIMED